GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » S Biomedics Co Ltd (XKRX:304360) » Definitions » EV-to-EBIT

S Biomedics Co (XKRX:304360) EV-to-EBIT : -70.93 (As of May. 17, 2024)


View and export this data going back to 2023. Start your Free Trial

What is S Biomedics Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, S Biomedics Co's Enterprise Value is ₩386,798 Mil. S Biomedics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-5,454 Mil. Therefore, S Biomedics Co's EV-to-EBIT for today is -70.93.

The historical rank and industry rank for S Biomedics Co's EV-to-EBIT or its related term are showing as below:

XKRX:304360' s EV-to-EBIT Range Over the Past 10 Years
Min: -87.85   Med: -20.85   Max: -12.2
Current: -70.92

During the past 6 years, the highest EV-to-EBIT of S Biomedics Co was -12.20. The lowest was -87.85. And the median was -20.85.

XKRX:304360's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs XKRX:304360: -70.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. S Biomedics Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩137,057 Mil. S Biomedics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-5,454 Mil. S Biomedics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.98%.


S Biomedics Co EV-to-EBIT Historical Data

The historical data trend for S Biomedics Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

S Biomedics Co EV-to-EBIT Chart

S Biomedics Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial - - - - -

S Biomedics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -22.20 -18.82 -25.13

Competitive Comparison of S Biomedics Co's EV-to-EBIT

For the Biotechnology subindustry, S Biomedics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


S Biomedics Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, S Biomedics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where S Biomedics Co's EV-to-EBIT falls into.



S Biomedics Co EV-to-EBIT Calculation

S Biomedics Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=386798.077/-5453.558
=-70.93

S Biomedics Co's current Enterprise Value is ₩386,798 Mil.
S Biomedics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


S Biomedics Co  (XKRX:304360) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

S Biomedics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-5453.558/137057.184
=-3.98 %

S Biomedics Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩137,057 Mil.
S Biomedics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


S Biomedics Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of S Biomedics Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


S Biomedics Co (XKRX:304360) Business Description

Traded in Other Exchanges
N/A
Address
Seongsui-ro 26-gil, 4th Floor, Wooil Venture Town Building 28, Seongdong-gu, FedEx building, Seoul, KOR, 04797
S Biomedics Co Ltd researches and develops cell therapies for regenerative biomedicine. It owns two platform technologies: Functionally Enhanced Cell Spheroid and Targeted Embryonic Stem Cell Differentiation for developing cell therapy products that overcome the limitations of existing cell therapy products.

S Biomedics Co (XKRX:304360) Headlines

No Headlines